Analysts Anticipate Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Will Announce Quarterly Sales of $24.66 Million
Wall Street analysts forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report $24.66 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $35.09 million and the lowest estimate coming in at $16.96 million. Lexicon Pharmaceuticals reported sales of $13.75 million in the same quarter last year, which indicates a positive year-over-year growth rate of 79.3%. The business is expected to issue its next quarterly earnings results on Monday, July 29th.
On average, analysts expect that Lexicon Pharmaceuticals will report full year sales of $92.62 million for the current fiscal year, with estimates ranging from $59.31 million to $175.35 million. For the next year, analysts forecast that the business will post sales of $103.80 million, with estimates ranging from $39.98 million to $154.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.21). The firm had revenue of $9.20 million during the quarter, compared to analyst estimates of $13.26 million. During the same quarter in the previous year, the business posted ($0.40) earnings per share. Lexicon Pharmaceuticals’s revenue for the quarter was down 63.8% compared to the same quarter last year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co acquired a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $73,000. First Manhattan Co. purchased a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $15,282,000. Clearbridge Investments LLC grew its holdings in Lexicon Pharmaceuticals by 3.4% in the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after purchasing an additional 42,540 shares during the period. Geode Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock valued at $3,752,000 after purchasing an additional 13,664 shares during the period. Finally, Gamco Investors INC. ET AL grew its holdings in Lexicon Pharmaceuticals by 10.0% in the first quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 98.27% of the company’s stock.
Shares of LXRX traded up $0.17 during midday trading on Monday, reaching $5.45. The stock had a trading volume of 265,687 shares, compared to its average volume of 685,128. Lexicon Pharmaceuticals has a 1-year low of $4.25 and a 1-year high of $13.13. The business has a fifty day moving average price of $5.88. The firm has a market capitalization of $579.18 million, a P/E ratio of -4.78 and a beta of 0.84.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Read More: What is the role of the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.